Abstract: Disclosed is a method for screening an immune modulator. More specifically, disclosed is a method of screening an immune modulator, an anticancer agent and an agent for treating autoimmune diseases, which regulate the cell surface expression level of gp96, using the binding of the region of amino acids 54-192 of AIMP1 to the region of amino acids 699-799 of AIMP1, set forth in SEQ ID NO: 18. Also disclosed is a method of diagnosing autoimmune diseases using the binding.

Abstract: This invention relates to compounds of Formula I having an aziridine-2-carboxylic group and a menthol group, a process for preparing such compounds, a method for obtaining optically active aziridine-2-carboxylate derivatives by optical resolution of such compounds, and optically active aziridine-2-carboxylate derivatives obtained by the same method: wherein R1 is hydrogen; alkyl; cycloalkyl; 4-chlorophenyl; 4-methoxyphenyl; s-triazinyl or pyridinyl acyl; benzyl; hydrocarbon residue which may be substituted with a substituent selected from the group consisting of hydroxy, alkoxy, dialkylamino, phenyl, 4-chlorophenyl and 4-methoxyphenyl; 2,4-dimethoxyphenyl; substituted phenyl including (1R)-phenylethyl or (1S)-phenylethyl. Preferences are given to (1R)-phenylethyl and (1S)-phenylethyl. Menthol is selected from the group consisting of (+)-menthol and (?)-menthol.

Abstract: The present invention relates to an immunological enhancement agent, more particularly, to an immunological enhancement agent comprising peptide having an amino acid sequence represented by SEQ ID NO:1 to SEQ ID NO:3 as an effective component. The peptides according to the present invention comprising the N-terminal domain of the p43 protein have excellent cytokine activity to improve an immune response so that they can be used as an effective immunological enhancement agent.

Abstract: The present invention relates to an immunological enhancement agent, more particularly, to an immunological enhancement agent comprising peptide having an amino acid sequence represented by SEQ ID NO:1 to SEQ ID NO:3 as an effective component.